G1 Therapeutics Provides First Quarter 2024 Financial Result

01.05.2024 - - Achieved $14.1 Million in Net Revenue from Sales of COSELA (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Announced That Updated Efficacy Results from Phase 2 Trial of Trilaciclib ...

Related Keywords

Japan , Ukraine , Jack Bailey , Johnw Umstead , Drug Administration On , Pepper Bio Inc , Investor Relations Corporate Communications , Therapeutics Inc , Exchange Commission , Nasdaq , Twitter , Drug Administration , That Final Analysis , Evaluating Overall Survival , Metastatic Triple Negative Breast Cancer , Late Second Quarter , Runway Expected , Third Quarter , Host Webcast , Conference Call , Chief Executive Officer , Runway Extends , Efficacy Results , Poster Presentation , New Drug Application , License Agreement , Pepper Bio , Private Securities Litigation Reform Act , Investor Relations , Months Ended March , G1 Therapeutics Chart , 1 Therapeutics Kurs , 1 Therapeutics Aktie ,